CJC-1295 research gets clearer with DAC in view.
Two little words, “with DAC”, change the story. I keep them next to any claim about how long CJC-1295 lasts.
Same name, different ingredients
CJC-1295 is a lab-made relative of a hormone that tells the pituitary, a small gland near the brain, to release growth hormone. That explains the interest. It doesn’t yet tell us whether using it helps someone.
DAC is a chemical attachment that helps it bind albumin, a protein in blood. The FDA treats the forms with and without DAC as different ingredients. Its review found no human study of the form without DAC.
So I leave the qualifier in. It’s a small bit of wording that keeps us attached to the right substance.
A week in the blood isn’t a plan
In healthy adults, the DAC form had a half-life of roughly six to eight days. Half-life means the time it takes for the measured amount to fall by half. It isn’t a safe interval between uses.
The study also found higher growth hormone and IGF-1, another growth-related signal. That shows the substance did something to the hormone system. Better sleep, fat loss and muscle gain were not the outcomes being tested.
The number is worth understanding. It just answers a narrower question than “will this help me?” That takes us back to the signal.
The pulses kept going
In a follow-up study in men, growth hormone still rose and fell in pulses during sustained stimulation. “Pulsatility” is the word researchers use for that pattern.
I find this easier to picture than a row of hormone averages. A higher average doesn’t tell the whole story of how a signal moves. The researchers were looking at its shape.
But the paper didn’t test better sleep or long-term health. Keeping a pulse pattern is an interesting finding. Calling it a benefit would add something the experiment didn’t measure.
The safety gaps travel with the findings
CJC-1295 has no FDA approval. The FDA review describes headaches, injection-site reactions and flushing. It also raises concerns about immune reactions. Small, early studies leave long-term safety unsettled.
The FDA page current as of April 22, 2026 lists CJC-1295 as nominated but withdrawn. The safety concerns remain beside it. Withdrawing a request is no approval or clearance for compounding.
For a conversation with a clinician, I’d keep the exact form and the health concern together. The comparison page helps put that question beside the other research without turning a half-life into a treatment plan.
Keep a question open for the next reading.